Special Issue

Invasion and Progression of Solid Tumors in Bone

Message from the Guest Editor

Invasion and progression of solid tumors in bone is a common phenomenon in cancer and the main cause of metastatic disease in breast and prostate cancer, the two most frequent cancers in western world. Bone metastases are often present in several other solid tumors, such as lung and kidney. Osteoclast activity stimulation by cancer cells is a key process in bone metastasis development and has become the most attractive hypothesis to explain bone fragility and test new pharmacological treatment approaches for bone metastases. A comprehensive medical approach to the effects of solid tumor invasion and progression in bone currently includes adequate pain management and selection of anticancer drugs in combination with bonetargeted treatments, as part of a multidisciplinary strategy also comprising radiotherapy and surgery whenever indicated. The current Special Issue asks for contributions that provide new insights into the ability of cancer cells to invade bone and on new tools to improve the clinical approach to patients with or at risk of bone metastases.

Guest Editor

Dr. Luís Costa

- 1. Director of Oncology Department of Hospital de Santa Maria, Lisbon, Portugal
- 2. Associate Professor of Medicine, Oncology & Oncobiology, Lisbon School of Medicine (FMUL) University of Lisbon, Lisbon, Portugal

Deadline for manuscript submissions

closed (31 May 2022)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/73973

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

